GOP's Lawler Takes Cannabis Cash, Then Calls Legalization 'Hurting' NY

October 1, 2026

Photo by oljamu via Pixabay.

Mike Lawler stood on a debate stage this week and said New York's legal marijuana law is hurting people. Nothing unusual about a Republican congressman taking that position -- except that some of the same companies he's effectively campaigning against, in rhetorical terms, are quietly helping fund the PAC spending money to keep him in office. That's not a coincidence worth glossing over. It's a snapshot of a pattern that's become increasingly common in GOP politics: cannabis companies writing checks to support Republicans who either oppose legalization outright or, like Lawler, say the thing is actively causing harm once it's already law. The industry isn't betting on ideology. It's betting on access, and the Lawler race in New York's 17th District is as clean an example of that bet as you'll find this cycle.

What Lawler Actually Said

During a News 12-hosted debate held over the evening of Monday, September 28 into September 29, 2026, moderator Tara Rosenblum put a direct question to both NY-17 candidates: is New York's legal marijuana program helping or hurting local economies and neighborhoods? Representative Mike Lawler and his Democratic challenger, Army veteran and former Biden administration national security official Mary Jo Conley, gave opposite answers. Conley said legalization has been a net positive for the district. Lawler said the opposite -- that it's hurting -- but didn't use his allotted time to back that up with specifics, no mention of crime data, youth usage rates, illicit market activity, or any of the usual talking points critics of legalization reach for. The exchange was brief, almost a throwaway moment, sandwiched into a debate that otherwise ranged across data centers, immigration enforcement, Social Security solvency, tariffs and the general cost of living squeezing Hudson Valley households. But brief doesn't mean inconsequential. It's a clean, on-the-record statement from a sitting congressman in a swing district, made days before FEC filings would reveal just how tangled his campaign's finances are with the industry he just criticized.

The PAC Spending Cannabis Money to Help Him Win

Photo by Alexas_Fotos via Pixabay.

The PAC in question is America First Agriculture Action Inc., and its leadership tells you most of what you need to know before you even get to the money. It shares a treasurer with Trump's own super PAC, placing it squarely inside Trump-world's political infrastructure rather than at some arm's-length distance. Its funding, according to FEC filings, comes entirely from marijuana businesses -- Trulieve, Curaleaf, Verano Holdings and Ascend Wellness among the named contributors, with additional money tied to Green Thumb Industries and AYR Wellness. In June alone, those companies collectively put $11.5 million into the PAC. Add that to other cannabis industry contributions flowing toward Trump-aligned committees, and the running total now sits at roughly $15.05 million. As of Monday, FEC filings show the PAC has spent $288,774.79, with a portion of that going toward supporting Lawler's reelection bid. Here's the detail that makes the whole arrangement feel almost absurd: the pro-Lawler ad funded by this cannabis-money PAC never once mentions cannabis. Instead it highlights his votes against congressional insider trading and for eliminating taxes on tips, overtime pay and Social Security benefits -- popular, poll-tested material that has nothing to do with the industry actually bankrolling the message.

Why a Pro-Cannabis PAC Would Hide the Word Cannabis

That omission isn't an oversight. It's a calculated bet that in a district like NY-17, economic populism sells better than a cannabis endorsement, and that some GOP primary voters still flinch at the word even as national polling shows majority support for legalization. So the companies funding the PAC get something quieter and arguably more valuable than a campaign ad shouting their name: a sitting congressman who owes them, win or lose on the messaging. This is the broader trend Marijuana Moment has tracked for a while now -- multistate operators pouring money into Trump-aligned committees and GOP candidates regardless of those candidates' actual legalization stance, because what they're purchasing is regulatory access and goodwill, not ideological alignment. You see the same dynamic elsewhere. A Texas Republican Senate candidate took alcohol industry money while actively opposing cannabis reform, a reminder that industry money in GOP races often flows toward whoever holds power rather than whoever shares the industry's goals. And in Nebraska's Senate race, an opponent's unsubstantiated claim tying legalization to child deaths became live campaign ammunition, which tells you how combustible this issue still is inside Republican primaries even as the money keeps moving.

The Rescheduling Backdrop

Photo by National Cancer Institute via Unsplash.

All of this is happening against a federal backdrop that makes the political maneuvering feel almost more urgent than it should. Trump signed an executive order in December 2025 directing the federal government to move marijuana from Schedule I to Schedule III under the Controlled Substances Act. Nearly a year later, that rescheduling process is stalled, stuck somewhere in the machinery of federal rulemaking without a clear timeline for completion. That stall matters here because it explains, at least partly, why multistate operators are spending tens of millions on PACs and candidate support rather than simply waiting for the administrative process to run its course. If rescheduling were moving briskly, the incentive to buy goodwill with individual members of Congress would be weaker. Instead, companies are hedging by building relationships with lawmakers who can intervene, delay, or shape outcomes regardless of where they personally land on legalization. Money flowing to a skeptic like Lawler only makes sense once you accept that the industry has largely stopped treating this as an ideological fight and started treating it as a straightforward access play, prioritizing short-term political relationships over any kind of consistency on reform itself.

NY-17 Is a Real Test Case

Photo by Saahil Khatkhate via Unsplash.

NY-17 is worth watching specifically because it's genuinely competitive, not a safe seat where this contradiction could pass unnoticed. Lawler flipped the district in the 2022 midterms and won reelection in 2024 with 52.1 percent of the vote, a margin thin enough that national Democrats and Republicans both treat the seat as one of the most winnable swing districts in the country heading into the midterms. Conley brings a distinct contrast beyond the cannabis question, with a military record and national security background from her time in the Biden administration that she's using to position herself as a steady hand on issues like Social Security and cost of living. But the cannabis thread here is its own kind of test. Voters in the district now have a documented gap to weigh: a congressman saying publicly that legalization is hurting people, while benefiting from a PAC funded entirely by the companies profiting from legalization elsewhere. It's also worth remembering that legal cannabis markets aren't uniform -- New York's program has had its own rollout troubles distinct from markets in Colorado, Michigan or Florida, so local economic impact claims should be checked against New York-specific data, not assumed from how legalization has played out in other states.

Campaign debates reward soundbites, not disclosures, which is exactly why Lawler could say legalization is hurting people without anyone on stage asking him to reconcile that with his own PAC's donor list. FEC filings don't have that problem. They show, dollar for dollar, who's funding whom and why, and in this case they show a cannabis industry writing seven-figure checks to help reelect a congressman willing to say the industry's product is bad for his constituents. Voters who actually care about where candidates stand on legalization would do better spending ten minutes on FEC.gov than listening to another debate exchange. The rhetoric is for show. The money is the tell.